Compare Evergy Inc. Common Stock (EVRG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Evergy Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? Evergy Inc. Common Stock trades at $82.56 (market cap $18.94B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Evergy Inc. Common Stock is far larger — about 5.2× Organon & Co. Common Stock's market cap, and Evergy Inc. Common Stock pays the higher dividend (3.38%). Which is the better fit depends on your goals — on Pluang, investors hold Evergy Inc. Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| EVRG | OGN | |
|---|---|---|
Market Cap | $18.94B | $3.62B |
Volume | 1,640,293 | 2,892,999 |
Sector | Utilities | Health |
52-Week High | $88.13 | $13.81 |
52-Week Low | $72.31 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $35.41B | $11.04B |
Dividend Yield | 3.38% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Evergy (EVRG) trades at $82.13, up 0.77% today, with a bullish technical signal and strong support near $80. The stock shows solid fundamentals with a P/E of 20.9 and net income margin of 15.19%, supported by recent earnings beats in Q1 and Q2 2026. Positive sentiment is driven by data center demand growth and a $21.6 billion investment plan, as highlighted in recent news.
The outlook for EVRG is positive, with analyst consensus pointing to a $89.83 price target and 38.89% buy ratings. Key opportunities include load growth from data center contracts and projected 6-8% EPS growth through 2030. Risks involve regulatory challenges, high capital expenditures, and potential volatility from interest rate sensitivity.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Evergy Inc. Common Stock
Evergy is a regulated electric utility serving customers in Kansas and Missouri. Its operations include electricity generation, transmission, and distribution through its integrated utility subsidiaries.
Read more on EVRG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
